

**6. Literaturverzeichnis**

1. Burkitt D. A sarcoma involving the jaws in African children. *Br J Surg* 1958;46(197):218-23.
2. Epstein MA, Achong BG, Barr YM. Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. *Lancet* 1964;15:702-3.
3. Epstein MA, Henle G, Achong BG, Barr YM. Morphological and Biological Studies on a Virus in Cultured Lymphoblasts from Burkitt's Lymphoma. *J Exp Med* 1965;121:761-70.
4. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-yppe virus to infectious mononucleosis. *Proc Natl Acad Sci U S A* 1968;59(1):94-101.
5. Greenspan JS, Greenspan D, Lennette ET, Abrams DI, Conant MA, Petersen V, Freese UK. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. *N Engl J Med* 1985;313(25):1564-71.
6. Ziegler JL, Drew WL, Miner RC, Mintz L, Rosenbaum E, Gershow J, Lennette ET, Greenspan J, Shillitoe E, Beckstead J, Casavant C, Yamamoto K. Outbreak of Burkitt's-like lymphoma in homosexual men. *Lancet* 1982;2(8299):631-3.
7. Rickinson AB, Moss,D.J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu Rev Immunol* 1997;15:405-31.
8. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Fields BN, Knipe DM, Howley PM, eds. *Virology*. Fourth ed. Philadelphia: Lippincott-Raven; 2001:2575-615.
9. Mosialos G, Birkenbach,M.,Yalamanchili,R.,VanArsdale,T.,Ware,C.,Kieff,E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. *Cell* 1995;80:389-99.
10. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. *New Engl J Med* 1998;338:1413-21.
11. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB, Kieff E. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. *Immun* 1995;2(2):155-66.
12. Levitskaya J, Coram,M.,Levitsky,V.,Imreh,S.,Steigerwald-Mullen,P.M., Klein,G., Kurilla,M.G., Masucci,M.G. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. *Nature* 1995;375:685-8.
13. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. *Science* 2003;301(5638):1371-4.

14. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. *Nat Rev Immunol* 2001;1(1):75-82.
15. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. *Proc Natl Acad Sci U S A* 2006;103(40):14935-40.
16. Nemerow GR, Wolfert R, McNaughton ME, Cooper NR. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). *J Virol* 1985;55(2):347-51.
17. Wolf H, Bogedain C, Schwarzmann F. Epstein-Barr virus and its interaction with the host. *Intervirology* 1993;35(1-4):26-39.
18. Cohen JI. Epstein-Barr virus infection. *N Engl J Med* 2000;343(7):481-92.
19. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. *J Virol* 2005;79(2):1296-307.
20. Deeg HJ, Socie'G. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. *Blood* 1998;91:1833-44.
21. Magrath I. The pathogenesis of Burkitt's lymphoma. *Adv Cancer Res* 1990;55:133-270.
22. de-The G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. *Nature* 1978;274(5673):756-61.
23. Chan JK, Tsang WY, Ng CS, Wong CS, Lo ES. A study of the association of Epstein-Barr virus with Burkitt's lymphoma occurring in a Chinese population. *Histopathology* 1995;26(3):239-45.
24. Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, Epelman S, Risueno C, Magrath IT. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. *Blood* 1992;79(12):3261-6.
25. Hamilton-Dutoit SJ, Raphael M, Audouin J, Diebold J, Lisse I, Pedersen C, Oksenhendler E, Marelle L, Pallesen G. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. *Blood* 1993;82(2):619-24.
26. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. *Embo J* 1987;6(9):2743-51.

27. Rowe M, Khanna R, Jacob CA, Argaet V, Kelly A, Powis S, Belich M, Croom-Carter D, Lee S, Burrows SR, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. *Eur J Immunol* 1995;25(5):1374-84.
28. Fu T, Voo KS, Wang RF. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. *J Clin Invest* 2004;114(4):542-50.
29. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. *Annu Rev Immunol* 1998;16:471-93.
30. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. *N Engl J Med* 1989;320(8):502-6.
31. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. *Nat Rev Immunol* 2003;3(10):801-12.
32. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. *Blood* 2005;106(13):4339-44.
33. Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. *Blood* 2005;106(13):4345-50.
34. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk BF, Vogelstein J. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. *N Engl J Med* 1989;320(11):689-95.
35. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. *Blood* 1998;92(7):2477-83.
36. Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla M, G., Bhardwaj N., Steinman R.M. Presentation of Epstein-Barr virus latency antigens to CD8+, interferon- $\gamma$ -secreting, T lymphocytes. *Eur J Immunol* 1999;29:3995-4001.
37. Roskrow MA, Suzuki N, Gan Y-j, Sixbey JW, Ng CYC, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's Disease. *Blood* 1998;91:2925-34.
38. Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. *Blood* 2000;95(1):241-8.

39. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. *J Immunother* 2004;27(4):317-27.
40. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. *J Exp Med* 2004;200(12):1623-33.
41. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. *Am J Pathol* 1995;146(6):1355-67.
42. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. *N Engl J Med* 1995;333(11):693-8.
43. Sam CK, Brooks LA, Niedobitek G, Young LS, Prasad U, Rickinson AB. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. *Int J Cancer* 1993;53(6):957-62.
44. Lee SP, Chan AT, Cheung ST, Thomas WA, CroomCarter D, Dawson CW, Tsai CH, Leung SF, Johnson PJ, Huang DP. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. *J Immunol* 2000;165(1):573-82.
45. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. *J Clin Oncol* 2005;23(35):8942-9.
46. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. *Blood* 2005;105(5):1898-904.
47. Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, Chen CL, Chang YS, Lee SP, Rickinson AB, Tam PK. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. *Cancer Res* 2002;62(23):6952-8.
48. Oertel SH, Riess H. Immunosurveillance, immunodeficiency and lymphoproliferations. *Recent Results Cancer Res* 2002;159:1-8.
49. Subklewe M, Marquis R, Choquet S, Leblond V, Garnier JL, Hetzer R, Swinnen LJ, Oertel S, Papp-Vary M, Gonzalez-Barca E, Hepkema BG, Schoenemann C, May J,

- Pezzutto A, Riess H. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. *Transplantation* 2006;82(8):1093-100.
50. Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. *Am J Surg Pathol* 1996;20(1):103-11.
51. Trappe R. OS, Riess H. Pathogenese, Klinik, Diagnostik und Therapie transplantationsassoziierter lymphoproliferativer Erkrankungen. *Deutsches Ärzteblatt* 2006;103 (48):2836-42.
52. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. *J Exp Med* 1999;190:567-76.
53. Poirel HA, Bernheim A, Schneider A, Meddeb M, Choquet S, Leblond V, Charlotte F, Davi F, Canioni D, Macintyre E, Mamzer-Bruneel MF, Hirsch I, Hermine O, Martin A, Cornillet-Lefebvre P, Patey M, Toupance O, Kemeny JL, Deteix P, Raphael M. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status. *Transplantation* 2005;80(2):176-84.
54. Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Jr., Hardesty RL, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. *Lancet* 1984;1(8377):583-7.
55. Papadopoulos EB, Ladanyi, M.Emanuel,D., Mackinnon,S., Boulad,F., Carabasi,M.H., Castro Malaspina, H.C., Childs, B.H., Gillio,A.P., Small,T.N., Young,J.W., Kernan,N.A., O'Reilly,R.J. Infusion of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. *N Engl J Med* 1994;330:1185-91.
56. Heslop HE, Ng,C.Y.C., Li,C.,Smith,C.A., Loftin,S.K.,Krance,R.A., Brenner,M.K., Rooney,C.M. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nat Med* 1996;2:551-5.
57. Rooney CM, Smith,C.A.,Ng,C.Y.C.,Loftin,S.K.,Sixbey,J.W.,Gan,Y.,Srivastava,D.-K.,Bowman,L.C.,Krance,R.A.,Brenner,M.K.,Heslop,H.E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. *Blood* 1998;92:1549-55.
58. Banchereau J, Steinman, R. M. Dendritic cells and the control of immunity. *Nature* 1998;392:245-52.

59. Galy A, Christopherson I, Ferlazzo G, Liu G, Spits H, Georgopoulos K. Distinct signals control the hematopoiesis of lymphoid-related dendritic cells. *Blood* 2000;95(1):128-37.
60. Spits H, Couwenberg F, Bakker AQ, Weijer K, Uittenbogaart CH. Id2 and Id3 inhibit development of CD34(+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre-DC2. *J Exp Med* 2000;192(12):1775-84.
61. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. *Nat Rev Immunol* 2002;2(3):151-61.
62. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y-J, Pulendran B, Palucka K. Immunobiology of dendritic cells. *Annu Rev Immunol* 2000;18:767-811.
63. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. *J Exp Med* 1976;143:1283-8.
64. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature* 1998;392:86-9.
65. Albert ML, Bhardwaj N. Resurrecting the Dead: DCs Cross-Present Antigen Derived From Apoptotic Cells on MHC I. *The Immunologist* 1998;6(5):194-8.
66. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Iltstad ST, Kast WM, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. *Nature Med* 1995;1:1297-302.
67. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. *J Exp Med* 1995;182:255-60.
68. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. *J Exp Med* 1996;183:317-22.
69. Specht JM, Do JS, Lam RE, Royal ME, Reeves SA, Rosenberg SA, Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastasis. *J Exp Med* 1997;186:1213-21.
70. Flammand V, Thielemans C, Demanet C, Bakkus M, Bazin H, Thielemans F, Leo O, Urbain J, Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. *Eur J Immunol* 1994(24):605-10.
71. Toes REM, van der Voort EIH, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJM. Enhancement of tumor

- outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. *J Immunol* 1998;160:4449-56.
72. Hsu FJ, Benike C, Fagnoni F, Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. *Nature Med* 1996;2:52-8.
  73. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. *Nat Med* 1998;4:328-32.
  74. Cardin RD, Brooks J.W., Sarawar S.R., Doherty P.C. Progressive loss of CD8+ T cell-mediated control of gamma-herpesvirus in the absence of CD4+ T cells. *J Exp Med* 1996;184:863-71.
  75. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. *Nature* 1998;393(6684):474-8.
  76. Bennett SRM, Carbone F.R., Karamalis F., Flavell R.A., Miller J.F.A.P., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* 1998;393:478-80.
  77. Schoenberger SP, Toes R.E.M., van der Voort E.I.H., Offringa R., Melief C.J.M. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. *Nature* 1998;393:480-3.
  78. Hamilton SE, Wolkers MC, Schoenberger SP, Jameson SC. The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. *Nat Immunol* 2006;7(5):475-81.
  79. Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Importance of CD4(+) T helper cell responses in tumor immunity. *Immunol Lett* 2000;74(1):75-9.
  80. Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dorken B, Riess H, Gartner B. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. *Ann Hematol* 2006;85(7):478-84.
  81. Vadheim CM, Rotter JI, Maclaren NK, Riley WJ, Anderson CE. Preferential transmission of diabetic alleles within the HLA gene complex. *N Engl J Med* 1986;315(21):1314-8.
  82. MacDonald MJ, Gottschall J, Hunter JB, Winter KL. HLA-DR4 in insulin-dependent diabetic parents and their diabetic offspring: a clue to dominant inheritance. *Proc Natl Acad Sci U S A* 1986;83(18):7049-53.

83. Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. *Proc Natl Acad Sci U S A* 1989;86(24):10049-53.
84. Ellis RJ, Varela-Calvino R, Tree TI, Peakman M. HLA Class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides. *Immunology* 2005;116(3):337-46.
85. Khanna D, Wu H, Park G, Gersuk V, Gold RH, Nepom GT, Wong WK, Sharp JT, Reed EF, Paulus HE, Tsao BP. Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. *Arthritis Rheum* 2006;54(4):1105-16.
86. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. *J Exp Med* 1998;188(11):2163-73.
87. Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. *Blood* 1997;90(9):3640-6.
88. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Schmaljohn A, William C, Steinman R.M., Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. *J Immunol* 1999;163:6762-8.
89. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. *Crit Rev Oncol Hematol* 2005;56(1):23-46.
90. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. *Nat Rev Immunol* 2004;4(1):24-34.
91. Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla MG, Bhardwaj N, Steinman RM. Presentation of Epstein-Barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes. *Eur J Immunol* 1999;29(12):3995-4001.
92. Munz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. *J Exp Med* 2000;191(10):1649-60.
93. Murray RJ, Kurilla MG, Griffin HM, Brooks JM, Mackett M, Arrand JR, Rowe M, Burrows SR, Moss DJ, Kieff E, Rickinson AB. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. *PNAS* 1990;87:2906-10.

94. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. *J Exp Med* 1992;176:157-68.
95. McCutcheon M, Wehner N, Wensky A, Kushner M, Doan S, Hsiao L, Calabresi P, Ha T, Tran TV, Tate KM, Winkelhake J, Spack EG. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. *J ImmunolMeth* 1997;210:149-66.
96. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. *J ImmunolMeth* 1997;210:167-74.
97. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. *Nat Immunol* 2004;5(9):927-33.
98. Bevan MJ. Helping the CD8(+) T-cell response. *Nat Rev Immunol* 2004;4(8):595-602.
99. Long HM, Haigh TA, Gudgeon NH, Leen AM, Tsang CW, Brooks J, Landais E, Houssaint E, Lee SP, Rickinson AB, Taylor GS. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. *J Virol* 2005;79(8):4896-907.
100. Nikiforow S, Bottomly K, Miller G, Munz C. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. *J Virol* 2003;77(22):12088-104.
101. Tsang CW, Lin X, Gudgeon NH, Taylor GS, Jia H, Hui EP, Chan AT, Lin CK, Rickinson AB. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. *J Virol* 2006;80(16):8263-6.
102. Heller KN, Upshaw J, Seyoum B, Zebroski H, Munz C. Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. *Blood* 2007;109(3):1138-46.
103. Sebelin-Wulf K, Nguyen T. D., Oertel S., Papp-Vary M., Schulzki A., Trappe R., Pezzutto A., Riess H., Subklewe M. Quantitative analysis of EBV-specific CD4 / CD8 T cell numbers, absolute CD4 / CD8 cell numbers and EBV load in solid organ transplant recipients with PTLD. *Transplant Immunology*:in press.
104. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, Rickinson AB, Leiner I, Pamer E, Lowenberg B, Cornelissen JJ, Gratama JW. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for

- progressive EBV reactivation and lymphoproliferative disease. *Blood* 2003;101(11):4290-7.
105. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, Sokal EM. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. *Transplantation* 2002;73(10):1603-10.
106. Macedo C, Donnenberg A, Popescu I, Reyes J, Abu-Elmagd K, Shapiro R, Zeevi A, Fung JJ, Storkus WJ, Metes D. EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. *Transpl Immunol* 2005;14(2):109-16.
107. Baudouin V, Dehee A, Pedron-Grossetete B, Ansart-Pirenne H, Haddad E, Maisin A, Loirat C, Sterkers G. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. *Transplantation* 2004;77(11):1706-13.
108. Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, Miedema F. Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. *Blood* 2002;99(7):2505-11.
109. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, Katlama C, Charlotte F, Dupont B, Brousse N, Huerre M, Mikol J, Camparo P, Mokhtari K, Tulliez M, Salmon-Ceron D, Boue F, Costagliola D, Raphael M. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. *Blood* 2001;98(8):2339-44.
110. van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, Niesters HG, Osterhaus AD, McMichael AJ, van Oers MH, Miedema F. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. *Blood* 2001;98(1):146-55.
111. Gautam A, Morrissey PE, Brem AS, Fischer SA, Gohh RY, Yango AF, Monaco AP. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. *Pediatr Transplant* 2006;10(5):613-6.
112. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. *J Clin Oncol* 2001;19(3):772-8.
113. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. *Transplantation* 1995;60(6):547-54.
114. Green M, Cacciarelli TV, Mazariegos GV, Sigurdsson L, Qu L, Rowe DT, Reyes J. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver

- transplant recipients during treatment for posttransplant lymphoproliferative disease. *Transplantation* 1998;66(12):1641-4.
115. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. *Blood* 2001;97(5):1165-71.
  116. Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, Verkade HJ. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. *Transpl Infect Dis* 2004;6(1):15-22.
  117. Loginov R, Aalto S, Piiparinen H, Halme L, Arola J, Hedman K, Hockerstedt K, Lautenschlager I. Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation. *J Clin Virol* 2006;37(2):104-8.
  118. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. *Am J Transplant* 2005;5(9):2222-8.
  119. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. *Transpl Infect Dis* 2001;3(2):79-87.
  120. Hornmark-Stenstam B, Landberg T, Low B. HLA antigens in Hodgkin's disease of very long survival. *Acta Radiol Oncol Radiat Phys Biol* 1978;17(4):283-8.
  121. Chan SH, Chew CT, Prasad U, Wee GB, Srinivasan N, Kunaratnam N. HLA and nasopharyngeal carcinoma in Malays. *Br J Cancer* 1985;51(3):389-92.
  122. Dardari R, Khyatti M, Jouhadi H, Benider A, Ettayebi H, Kahlain A, Mansouri A, El Gueddari B, Benslimane A. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. *Int J Cancer* 2001;92(2):294-7.
  123. Papasteriades C, Kaloterakis A, Filiotou A, Economidou J, Nicolis G, Trichopoulos D, Stratigos J. Histocompatibility antigens HLA-A, -B, -DR in Greek patients with Kaposi's sarcoma. *Tissue Antigens* 1984;24(5):313-5.
  124. Kaloterakis A, Papasteriades C, Filiotou A, Economidou J, Hadjiyannis S, Stratigos J. HLA in familial and nonfamilial Mediterranean Kaposi's sarcoma in Greece. *Tissue Antigens* 1995;45(2):117-9.
  125. Cortesini R, LeMaout J, Ciubotariu R, Cortesini NS. CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. *Immunol Rev* 2001;182:201-6.

126. Xystrakis E, Dejean AS, Bernard I, Druet P, Liblau R, Gonzalez-Dunia D, Saoudi A. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. *Blood* 2004;104(10):3294-301.
127. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. *J Exp Med* 1993;177(2):557-60.
128. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. *Mol Immunol* 1997;34(5):391-9.
129. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. *Blood* 1998;91(10):3574-81.
130. Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Munz C. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. *Hum Immunol* 2005;66(9):938-49.
131. Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Munz C. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. *J Exp Med* 2001;193(3):405-11.
132. Perez-Diez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. *Cancer Res* 1998;58(23):5305-9.
133. Bickham K, Munz C. Contrasting roles of dendritic cells and B cells in the immune control of Epstein-Barr virus. *Curr Top Microbiol Immunol* 2003;276:55-76.
134. Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D. Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. *Am J Transplant* 2003;3(11):1369-77.
135. Bickham K, Goodman K, Paludan C, Nikiforow S, Tsang ML, Steinman RM, Munz C. Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro. *J Exp Med* 2003;198(11):1653-63.
136. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. *Nature* 1999;398(6722):77-80.
137. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. *Nature* 1998;392(6671):86-9.

138. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. *Nature Cell Biol* 1999;1:362-8.
139. Schirmbeck R, Melber K, Reimann J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. *Eur J Immunol* 1995;25:1063-70.
140. Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A, Steigerwald-Mullen P, Kurilla M G, Frappier L, Rickinson A. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the [Gly-Ala]-containing protein requires exogenous processing. *Immunol* 1998;7:791-802.
141. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. *Blood* 2000;96(5):1857-64.
142. Subklewe M, Chahroudi A, Schmaljohn A, Kurilla MG, Bhardwaj N, Steinman RM. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. *Blood* 1999;94(4):1372-81.
143. Sebelin K, Schulzki A, Kloetzel PM, Dorken B, Pezzutto A, Subklewe M. Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients. *Transplantation* 2006;82(6):779-87.
144. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. *Eur J Immunol* 1997;27:3135-42.
145. Bonini C, Lee SP, Riddell SR, Greenberg PD. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. *J Immunol* 2001;166(8):5250-7.
146. Hackstein H, Renner FC, Bohnert A, Nockher A, Frommer T, Bein G, Weimer R. Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: results of a prospective matched-cohort study. *Am J Transplant* 2005;5(12):2945-53.
147. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. *J Exp Med* 1996;183(1):317-22.
148. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G. Vaccination with Mage-3A1 peptide-pulsed mature,

- monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 1999;190:1669-78.
149. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. *Blood* 2000;96(9):3102-8.
150. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. *Blood* 2002;99(5):1517-26.
151. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK. Expansion of melanoma-specific cytolytic CD8<sup>+</sup> T cell precursors in patients with metastatic melanoma vaccinated with CD34<sup>+</sup> progenitor-derived dendritic cells. *J Exp Med* 2004;199(11):1503-11.
152. Palucka AK, Laupeze B, Asford C, Saito H, Jego G, Fay J, Paczesny S, Pascual V, Banchereau J. Immunotherapy via dendritic cells. *Adv Exp Med Biol* 2005;560:105-14.